Population dynamics of serologically identified coinfections with human papillomavirus types 11, 16, 18 and 31 in fertile-aged Finnish women

被引:18
作者
Kaasila, Marjo [1 ]
Koskela, Pentti [1 ]
Kirnbauer, Reinhard [2 ]
Pukkala, Eero [3 ]
Surcel, Heljae-Marja [1 ]
Lehtinen, Matti [1 ,4 ]
机构
[1] Natl Inst Hlth & Welf, Oulu 90220, Finland
[2] Univ Vienna, Sch Med, Vienna, Austria
[3] Finnish Canc Registry, Inst Stat & Epidemiol Canc Res, FIN-00170 Helsinki, Finland
[4] Univ Tampere, Sch Publ Hlth, FIN-33101 Tampere, Finland
关键词
coinfection; competition; human papillomavirus; population; serology; CERVICAL-CANCER; HPV TYPE-16; PARTICLE VACCINE; CHLAMYDIA-TRACHOMATIS; SUSTAINED EFFICACY; RISK; INFECTION; DNA; ACQUISITION; FINLAND;
D O I
10.1002/ijc.24539
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Licensed human papillomavirus (HPV) vaccines are expected to prevent high-risk (hr) HPV-infections (most notably types 16 and 18). Whether HPV vaccination will change the distribution of hrHPVs at the population level is open, since competition between HPV types is not well understood. Two stratified random subcohorts (1983-1997 and 1995-2003) of 7,815 and 3,252 women with a minimum of 2 pregnancies (<32 years) were selected from the Finnish Maternity Cohort. Using ELISA based on virus-like particles (VLP), we determined antibodies to HPV 11, 16, 18 and 31 in paired sera of the women and used Poisson regression models to estimate the risk of further infection with other HPV types in those positive for HPV16 or HPV18 at baseline. Baseline HPV16 seropositivity was associated with increased risk of later infections with HPV18 (3.1, 95% Cl: 1.7, 5.6). HPV18 seropositivity was associated with increased risk of HPV16 (3.9, 95% Cl: 2.5, 6.1). Our observations favor a coinfection rather than superinfection model for the different HPV types and are not suggestive for type-replacement following HPV vaccination. (C) 2009 UICC
引用
收藏
页码:2166 / 2172
页数:7
相关论文
共 50 条
[1]  
af Geijersstam V, 1998, J INFECT DIS, V177, P1710, DOI 10.1086/517428
[2]  
AMHEIM L, 2005, THESIS KAROLINSKA I
[3]  
Anttila A, 1999, INT J CANCER, V83, P59, DOI 10.1002/(SICI)1097-0215(19990924)83:1<59::AID-IJC12>3.3.CO
[4]  
2-E
[5]   Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: Mathematical modelling analyses [J].
Barnabas, Ruanne V. ;
Laukkanen, Paivi ;
Koskela, Pentti ;
Kontula, Osmo ;
Lehtinen, Matti ;
Garnett, Geoff P. .
PLOS MEDICINE, 2006, 3 (05) :624-632
[6]   The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women [J].
Carter, JJ ;
Koutsky, LA ;
Wipf, GC ;
Christensen, ND ;
Lee, SK ;
Kuypers, J ;
Kiviat, N ;
Galloway, DA .
JOURNAL OF INFECTIOUS DISEASES, 1996, 174 (05) :927-936
[7]   Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection [J].
Carter, JJ ;
Koutsky, LA ;
Hughes, JP ;
Lee, SK ;
Kuypers, J ;
Kiviat, N ;
Galloway, DA .
JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (06) :1911-1919
[8]   HPV type-distribution in women with and without cervical neoplastic diseases [J].
Clifford, Gary ;
Franceschi, Silvia ;
Diaz, Mireia ;
Munoz, Nubia ;
Villa, Luisa Lina .
VACCINE, 2006, 24 :26-34
[9]   Human papillomavirus types in invasive cervical cancer worldwide:: a meta-analysis [J].
Clifford, GM ;
Smith, JS ;
Plummer, M ;
Muñoz, N ;
Franceschi, S .
BRITISH JOURNAL OF CANCER, 2003, 88 (01) :63-73
[10]   High incidence of cervical human papillomavirus infection in women during their first sexual relationship [J].
Collins, S ;
Mazloomzadeh, S ;
Winter, H ;
Blomfield, P ;
Bailey, A ;
Young, LS ;
Woodman, CBJ .
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2002, 109 (01) :96-98